Reactions 1704, p52 - 2 Jun 2018 Development of drug resistance: 28 case reports In a study, 28 patients (24 boys and 4 girls) aged 1 17 years [not all ages stated] were described, who developed resistance to asparaginase [L-asparaginase], daunorubicin and vincristine during treatment of T-cell acute lymphoblastic leukaemia (T- ALL) [routes, dosages and time to reaction onset not stated]. The patients, who had T-ALL, started receiving induction phase treatment with four dosages of vincristine, four dosages of daunorubicin and eight dosages of asparaginase from day 1 to day 33. Initially, the favourable treatment response was observed. Subsequently, the patients started receiving consolidation phase treatment with various drugs. After 78 days of the induction therapy, the patients were found to be positive for minimal residual disease analysis along with an over-expression of aldo-keto reductase 1C 1-3 (AKR1C1-3) enzyme, which was considered to be induced by the induction phase of treatment. Based on these findings, development of resistance to vincristine asparaginase and daunorubicin was considered. Author comment: "Further exploring the connection between AKR1C1-3 and the phenomenon of drug resistance, we found that drugs (daunorubicin, vincristine, and asparaginase) used as first-line treatment during induction therapy in paediatric T-ALL induced overexpression/activation of AKR1C1-3." "AKR1C1-3 are overexpressed in T-ALL cells from therapy-resistant patients." Bortolozzi R, et al. AKR1C enzymes sustain therapy resistance in paediatric T- ALL. British Journal of Cancer 118: 985-994, No. 7, Apr 2018. Available from: URL: http://doi.org/10.1038/s41416-018-0014-0 - Italy 803323224 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera